EMA Releases Final Guidance on Insulin Biosimilars

Drug Industry Daily
A A
Manufacturers of biosimilar insulin-containing products must demonstrate pharmacodynamic and pharmacokinetic similarity profiles to prove similar efficacy to their reference insulin, the European Medicines Agency says in final guidance issued this week.

To View This Article:

Login

Subscribe To Drug Industry Daily